224
Views
12
CrossRef citations to date
0
Altmetric
Editorial

TLR3 agonists and proinflammatory antitumor activities

, , , , , , & show all
Pages 481-483 | Published online: 19 Mar 2013

Bibliography

  • Matsumoto M, Funami K, Tanabe M, Subcellular localization of toll-like receptor 3 in human dendritic cells. J Immunol 2003;171(6):3154-62
  • Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity 2007;27(3):370-83
  • Cheng YS, Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 2010;10(12):1219-23
  • Cheadle EJ, Jackson AM. Bugs as drugs for cancer. Immunology 2002;107(1):10-19
  • Chin AI, Miyahira AK, Covarrubias A, Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010;70(7):2595-603
  • Paone A, Starace D, Galli R, Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008;29(7):1334-42
  • Salaun B, Coste I, Rissoan MC, TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176(8):4894-901
  • Van DN, Roberts CF, Marion JD, Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. FASEB J 2012;26(8):3188-98
  • Inao T, Harashima N, Monma H, Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer. Breast Cancer Res Treat 2012;134(1):89-100
  • Nomi N, Kodama S, Suzuki M. Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol Rep 2010;24(1):225-31
  • Forte G, Rega A, Morello S, Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer. J Immunol 2012;188(11):5357-64
  • Wang C, Zhuang Y, Zhang Y, Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 2012;30(32):4790-9
  • Robinson RA, DeVita VT, Levy HB, A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976;57(3):599-602
  • Hawkins MJ, Levin M, Borden EC. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod 1985;4(6):664-8
  • Butowski N, Lamborn KR, Lee BL, A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 2009;91(2):183-9
  • Strayer DR, Carter WA, Brodsky I, A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18(Suppl 1):S88-95
  • Shime H, Matsumoto M, Oshiumi H, Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 2012;109(6):2066-71

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.